ArticleFrontiers in pharmacology2022

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china.

Yamin Shu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.